• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Immunol . Type I IFNs Decrease SARS-CoV-2 Replication in Human Cardiomyocytes and Increase Cytokine Production in Macrophages

tetano

Editor, Senior Moderator
J Clin Immunol


. 2025 Oct 21;45(1):149.
doi: 10.1007/s10875-025-01943-6. Type I IFNs Decrease SARS-CoV-2 Replication in Human Cardiomyocytes and Increase Cytokine Production in Macrophages

Verónica Durán[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Eirini Nikolouli[SUP] #[/SUP][SUP] 4 [/SUP], Shambhabi Chatterjee[SUP] #[/SUP][SUP] 5 6 [/SUP], Bibiana Costa[SUP] 1 [/SUP], Andreas Pavlou[SUP] 1 [/SUP], Annett Ziegler[SUP] 1 [/SUP], Jennifer Becker[SUP] 1 [/SUP], Kira Baumann[SUP] 1 [/SUP], Matthias Bruhn[SUP] 1 [/SUP], Kathrin Haake[SUP] 7 [/SUP], Anna Rafiei Hashtchin[SUP] 7 [/SUP], Ingrid Gensch[SUP] 4 [/SUP], Andrea Korte[SUP] 5 [/SUP], Yvonne Lisa Behrens[SUP] 8 [/SUP], Shen-Ying Zhang[SUP] 9 10 11 [/SUP], Jean-Laurent Casanova[SUP] 9 10 11 12 13 [/SUP], Christian Bär[SUP] 5 6 [/SUP], Nico Lachmann[SUP] #[/SUP][SUP] 4 6 14 15 [/SUP], Thomas Thum[SUP] #[/SUP][SUP] 5 6 [/SUP], Ulrich Kalinke[SUP] #[/SUP][SUP] 16 17 [/SUP]



Affiliations
Abstract

The cellular basis of COVID-19 severity in patients with deficiencies in type I IFN immunity remains unclear. In this study, we differentiated cardiomyocytes and macrophages from IFNAR1 competent (IFNAR1[SUP]comp[/SUP]) and deficient (IFNAR1[SUP]def[/SUP]) induced pluripotent stem cells (iPSCs), and analyzed virus replication and cytokine production after exposure to SARS-CoV-2. Cardiomyocytes expressed the SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) and showed abundant SARS-CoV-2 replication, which was higher in IFNAR1[SUP]def[/SUP] than IFNAR1[SUP]comp[/SUP] cells. Treatment with exogenous IFNα mitigated infection in IFNAR1[SUP]comp[/SUP], but not in IFNAR1[SUP]def[/SUP] cardiomyocytes. In contrast, macrophages did not express ACE2 and did not support SARS-CoV-2 replication, but produced pro-inflammatory cytokines upon virus exposure, which was impaired in IFNAR1[SUP]def[/SUP] macrophages. In conclusion, type I IFNs decrease SARS-CoV-2 replication in human iPSC-derived cardiomyocytes, while they increase cytokine responses of macrophages.


 
Back
Top Bottom